Sequoia Vaccines

Executive Summary

Sequoia Vaccines is a clinical-stage biopharmaceutical company based in San Diego, focused on developing novel vaccines to prevent bacterial infections, particularly recurrent urinary tract infections (UTIs), as well as small molecule therapies for the treatment of certain cancers and lung infections associated with cystic fibrosis. The company was founded in 2020 and is currently in Phase 1 development, operating as a private entity. While specific pipeline details remain undisclosed, the company's dual focus on vaccine and small molecule platforms positions it in the competitive preventive and therapeutic infectious disease and oncology markets. Sequoia Vaccines' approach leverages proprietary technology to address significant unmet needs in UTI prevention and CF-related lung infections, areas with limited effective options. As a private company with no disclosed funding rounds or valuation, its progress is currently opaque, but its clinical-stage status suggests ongoing or impending data readouts that could serve as value-inflection points.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 data readout for lead UTI vaccine candidate40% success
• Q4 2026Series A or B financing round closure60% success
• H1 2027FDA IND clearance for cystic fibrosis lung infection small molecule program50% success